Gene therapy for muscular diseases

The “Gene Therapy for Muscular Diseases” team at UMR 1089 is currently focused on translational research to treat Duchenne Muscular Dystrophy (DMD) using gene therapy.

DMD is an X-linked inherited disease affecting about 1:5,000 male births. It is caused by mutations in the DMD gene coding for dystrophin, a cytoskeletal protein that is critical for the stability and function of muscle cells. DMD patients develop muscle weakness during the first years of life, and although palliative treatments are available, they become wheelchair-bound before the age of 15 years. DMD is characterized by a highly life-threatening muscle wasting condition (walking loss, respiratory and cardiac complications). To date, no effective treatment has yet been established, and the current symptomatic management of the disease remains still insufficient.

Gene therapy, which could target the genetic defect itself, appears today as a relevant alternative/complementary therapeutic strategy. Recombinant adeno-associated virus (rAAV) vectors are particularly efficient in transducing skeletal muscle fibers but also cardiomyocytes, and allow long term in vivo transgene expression.


In collaboration with several French and international laboratories our team is currently involved in the preclinical evaluation of several rAAV-based gene therapy products for DMD:

  • rAAV-U7 exon skipping (the selective removal of exons flanking an out-of frame DMD mutation)
  • rAAV-micro/mini-dystrophins (shortened transgenes, coding for partially functional dystrophin)
  • some new products targeting the calcium defects observed in DMD

The goal of our studies is to demonstrate the efficacy and the safety of these therapeutic products (including pharmacokinetics and pharmacodynamics), while optimizing their mode of delivery and the injected dosed, to finally provide results from proof of concept phases to the beginning of Phase I/II clinical trials in DMD patients. In order to perform such studies, part of our work also consists in better characterizing the models (in vitro and in vivo) that are used for these evaluations.

Our team has particular expertise in

  • Evaluation of in vitro & in vivo functionality of gene therapy products
  • In vivo experiments global coordination
  • Evaluation of gene therapy product biodistribution in tissues & shedding in biological fluids following in vivo administration
  • Evaluation of gene expression profile
  • Analysis of calcium-related events in skeletal and cardiac muscles
  • Pre-clinical IND writing.
Of note, all our studies are conducted under ISO 9001, version 2015 approved quality system.

Team members

Caroline Le Guiner, PhD, HDR, Team leader
Bodvaël Fraysse, PhD, Senior scientist, Co-scientific team leader
Corinne Huchet, PhD, HDR, Teacher and senior scientist
Audrey Bourdon, PhD
Tiphaine Girard, Technician
Kévin Martinais, Technician
Yann Péréon, MD, PhD, PU-PH, Associate researcher

Mis à jour le 26 January 2024.